Lupin Limited (Lupin) announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the U.S. (IQVIA MAT February 2024).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,662 INR | +1.38% | +4.90% | +25.60% |
13/05 | Lupin Relaunches Mirabegron ER Tablets in US | MT |
09/05 | Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.60% | 895.32Cr | |
+35.01% | 71TCr | |
+30.50% | 60TCr | |
-2.60% | 37TCr | |
+20.83% | 33TCr | |
+5.69% | 29TCr | |
+14.47% | 24TCr | |
+9.41% | 21TCr | |
-3.68% | 20TCr | |
+10.77% | 17TCr |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration